Characterization of cerebral glucose dynamics in vivo with a four-state conformational model of transport at the blood-brain barrier by Duarte, Joao M. N. & Gruetter, Rolf
Maintaining normal brain function requires glucose that is
supplied from blood through facilitative glucose carrier
proteins located at the blood–brain barrier (BBB), namely
glucose transporter type 1 (GLUT1; Pardridge et al. 1990;
Simpson et al. 2007). Over the two last decades, non-
invasive in vivo NMR techniques have been used to measure
glucose concentration and its transport and metabolism in the
brain of both humans (e.g. Gruetter et al. 1996, 1998, 2001;
Shestov et al. 2011) and rodents (e.g. Choi et al. 2002;
Duarte et al. 2009a, 2011a; Lei et al. 2010). For that,
mathematical models of glucose transport across the BBB
were initially based on irreversible Michaelis–Menten (MM)
kinetics (e.g. Lund-Andersen 1979; Mason et al. 1992;
Gruetter et al. 1996). These were abandoned because in
certain experimental conditions brain glucose concentrations
on the order of the KM of glucose carriers were observed, and
a reversible MM kinetics was thus introduced to describe
brain glucose transport as observed in vivo namely by NMR
spectroscopy (Cunningham et al. 1986; Gruetter et al. 1998).
However, some studies found that such kinetics failed to
determine the apparent affinity constant of glucose transport
Kt (Seaquist et al. 2001; Choi et al. 2002; Lei and Gruetter
2006; Shestov et al. 2011), which often largely diverged
from the KM for glucose transport determined in vitro (e.g.
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Abstract
Determination of brain glucose transport kinetics in vivo at
steady-state typically does not allow distinguishing apparent
maximum transport rate (Tmax) from cerebral consumption
rate. Using a four-state conformational model of glucose
transport, we show that simultaneous dynamic measurement
of brain and plasma glucose concentrations provide enough
information for independent and reliable determination of the
two rates. In addition, although dynamic glucose homeosta-
sis can be described with a reversible Michaelis–Menten
model, which is implicit to the large iso-inhibition constant
(Kii) relative to physiological brain glucose content, we found
that the apparent affinity constant (Kt) was better determined
with the four-state conformational model of glucose transport
than with any of the other models tested. Furthermore, we
confirmed the utility of the present method to determine
glucose transport and consumption by analysing the modu-
lation of both glucose transport and consumption by anaes-
thesia conditions that modify cerebral activity. In particular,
deep thiopental anaesthesia caused a significant reduction
of both Tmax and cerebral metabolic rate for glucose con-
sumption. In conclusion, dynamic measurement of brain
glucose in vivo in function of plasma glucose allows robust
determination of both glucose uptake and consumption
kinetics.
Keywords: blood–brain barrier, CMRglc, glucose transport,
GLUT, mathematical modelling, nuclear magnetic resonance.
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Gould et al. 1991; Lee et al. 1997). Reversible MM kinetics
does not consider iso-inhibition or trans-acceleration, in
contrast to the conformational four-state exchange kinetic
model of simple solute carriers that has been proposed to
describe glucose transport across the BBB (Barros et al.
2007; Duarte et al. 2009b).
Glucose transport kinetics as measured in vivo by 1H NMR
spectroscopy has been mostly determined under steady-state
conditions (Gruetter et al. 1998; Seaquist et al. 2001; Choi
et al. 2002; Lei and Gruetter 2006; Lei et al. 2010).
However, steady-state transport measurement from brain
glucose (Gbrain) content did not allow determining the
maximum transport rate separately from the glucose con-
sumption rate. Consequently, a ratio between the two was
estimated and often a constant cerebral metabolic rate of
glucose (CMRglc) has been assumed to allow determination
of an apparent maximum transport rate (Tmax) (e.g. Gruetter
et al. 1998; Duarte et al. 2009a; Lei et al. 2010). Gruetter
et al. (1996) determined glucose transport kinetics from
changes in brain glucose content measured using 1H NMR
difference spectroscopy after a rapid increase in plasma
glucose concentration. This method had the advantage of
providing a dynamic measure of Gbrain, which allowed the
determination of both Tmax and CMRglc using, at that time, an
irreversible MM kinetics for the glucose carriers at the BBB
(Gruetter et al. 1996). These experiments were recently
repeated by Shestov et al. (2011), who determined both Tmax
and CMRglc rates using the reversible MM model applied to
brain glucose concentrations measured by dynamic 1H NMR
spectroscopy. These authors, however, failed to determine Kt,
which was then estimated from previously reported steady-
state experiments (Gruetter et al. 1998; de Graaf et al. 2001).
Therefore, we tested the hypothesis that simultaneous
dynamic measurement of brain and plasma glucose concen-
trations in vivo allows to determine independent rates for
both glucose transport and consumption, that is, Tmax and
CMRglc, as well as Kt and Kii, using the four-state
conformational model of the glucose carrier.
Materials and methods
Animals
All experimental procedures involving animals were approved by
the local ethics committee. The experiments were performed with
special care to minimise animal pain or discomfort. Male Sprague–
Dawley rats (259.0 ± 5.8 g, n = 14, obtained from Charles River
Laboratoires, France) were prepared as previously described (Duarte
et al. 2009a, 2011a). Briefly, rats were anaesthetized using 2% (v/v)
isoflurane (Attane, Minrad, NY, USA) in 30% (v/v) oxygen in air,
and then intubated with an endotracheal catheter and ventilated with
a pressure-driven ventilator (MRI-1; CWE Inc., Ardmore, PA,
USA). Polyethylene catheters were inserted into a femoral artery for
monitoring blood gases, arterial blood pressure, and glucose and
lactate concentrations, and into a femoral vein for infusion of saline
solutions containing a-chloralose (Acros Organics, Geel, Belgium)
or D-glucose (Sigma-Aldrich, Basel, Switzerland).
Animals were immobilised in a home-built holder with a bite bar
and two ear inserts to minimize potential motion. Body temperature
was maintained around 37.5C with a warm water circulation
system based on the feedback obtained from a homebuilt rectal
temperature probe. Arterial blood pressure, heart rate and respiratory
rate were continuously measured with an animal monitoring system
(SA Instruments, Stony Brook, NY, USA).
Anaesthesia was switched to a-chloralose consisting of an
intravenous bolus of 80 mg/kg and continuous infusion rate of
28 mg/kg/h (Duarte et al. 2009a, 2011a). Before NMR measure-
ments, animals were allowed to stabilize for at least 40 min to avoid
remaining effects of isoflurane. D-Glucose [20% (w/v) in saline
solution] was given as a bolus and then continuously infused at a
rate adjusted based on concomitantly measured arterial plasma
glucose concentrations to maintain a stable plasma glucose
concentration. Arterial pH and pressures of O2 and CO2 were
measured using a blood gas analyser (AVL Compact 3; Diamond
Diagnostics, Holliston, MA, USA). Plasma glucose and lactate
concentrations were quantified by the glucose oxidase and lactate
oxidase methods, respectively, using two multi-assay analysers
(GW7 Micro-Stat; Analox Instruments, London, UK).
To modulate glucose transport and consumption, these experi-
ments were then repeated either under isoflurane or deep thiopental
anaesthesia instead of a-chloralose. Sodium thiopental (Ospedalia
AG, Hunenberg, Switzerland) was given as an intra-venous bolus of
50 mg/kg which was followed by 80 mg/kg/h continuous rate
infusion. This thiopental dose was found to induce iso-electricity
after 90 min of infusion, as determined by electroencephalography
in a previous study (Lei et al. 2010). Therefore, NMR measure-
ments were only initiated after 90 min under thiopental anaesthesia.
For experiments under isoflurane anaesthesia, rats were allowed to
spontaneously breathe 1.5% (v/v) isoflurane [in mixture of 30% (v/
v) oxygen in air]. Physiological parameters were similar between the
three experimental groups, with exception of plasma lactate
concentration (Table 1).
NMR spectroscopy
All experiments were performed in a Direct Drive spectrometer
(Agilent, Palo Alto, CA, USA) interfaced to an actively shielded 9.4
T magnet with a 31 cm horizontal bore (Magnex Scientific,
Abingdon, UK) using a homebuilt 12 mm 1H quadrature surface
coil. The rat brain was positioned in the isocentre of the magnet and
fast-spin-echo images with repetition time of 5 s, echo time of
52 ms and echo train length of 8 allowed to identify anatomical
landmarks, which were used to place the volume of interest (VOI) in
the cortex and hippocampus. Shimming was performed with
FAST(EST)MAP (Gruetter and Tka´c 2000), and 1H NMR spectra
were acquired from a VOI size of 120 lL using SPECIAL
(Mlyna´rik et al. 2006) with echo time of 2.8 ms and repetition
time of 4 s. Spectra were saved in blocks of eight scans, corrected
for the B0 drift and summed at a convenient time resolution.
Spectral analysis was carried out using LCModel (Stephen
Provencher Inc., Oakville, Ontario, Canada) including a macromol-
ecule spectrum in the database (Mlyna´rik et al. 2006). The
unsuppressed water signal measured from the same VOI was used
as internal reference for absolute quantification of 20 metabolites:
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glucose, c-aminobutyrate, alanine, N-acetylaspartate, N-acetylaspar-
tylglutamate, ascorbate, aspartate, creatine, glutamate, glutamine,
glutathione, glycerophosphorylcholine, b-hydroxybutyrate, myo-
inositol, scyllo-inositol, lactate, phosphocreatine, phosphorylcho-
line, phosphorylethanolamine, taurine (see details in Duarte et al.
2011c). As the inclusion of glucose H1a resonance at 5.23 ppm
does not significantly contribute for the reliability in the estimation
of glucose concentration (analysed by Shestov et al. 2011),
LCModel analysis was performed using the spectral range between
0.5 and 4.5 ppm, thus avoiding spectral manipulation for residual
water peak removal. The Crame´r-Rao lower bound (CRLB)
provided by LCModel for each metabolite was used as measure of
the reliability of the quantified metabolite concentration.
Kinetic model of glucose transport
The BBB was assumed to behave as a single membrane separating
the blood circulation compartment from the brain aqueous phase.
This is in agreement with a relatively small distribution space for
glucose inside endothelial cells, a fast rate of transport compared
with endothelial glucose consumption and glucose carriers largely
more concentrated in the membrane of brain cells than in luminal or
abluminal membranes of the endothelium (discussed in Gjedde and
Christensen 1984; Barros et al. 2007; Simpson et al. 2007).
Therefore, diffusion across cell membranes of astrocytes and
neurons is not limiting for the global rate of glucose transport,
consistent with similar intra- and extracellular glucose concentra-
tions (e.g. Pfeuffer et al. 2000).
Transport across the BBB was described using unidirectional
fluxes and symmetric kinetic constants for influx and efflux, as in
previous studies (e.g. Cunningham et al. 1986; Mason et al. 1992;
Gruetter et al. 1998; Duarte et al. 2009b). Briefly, glucose selec-
tively binds to facilitative glucose carriers that mediate solute
movement in both directions of the BBB along a concentration
gradient, which is maintained by continuous phosphorylation of
intracellular glucose (e.g. Gruetter et al. 1998; Barros et al. 2007;
Duarte et al. 2009b). Considering that the BBB is defined as a single
membrane (discussed in Duarte et al. 2009b), brain glucose
concentration (Gbrain) over time is defined by
dGbrainðtÞ
dt
¼ Tf  Tr  CMRglc ð1Þ
where Gbrain is given in lmol/g and the rates of glucose influx (T
f) or
efflux (Tr) across the BBB, as well as CMRglc, are in lmol/g/min.
Figure 1 represents the alternating-conformation model for a
membrane carrier in which the carrier protein may occur in four
distinct conformations: when unloaded, it can exist in two inter-
converting isomers that are ready to bind glucose either outside or
inside the membrane; when bound to glucose, it can assume two
conformations favouring glucose release to the outer or inner sides
of the membrane (e.g. Cuppoletti and Segel 1975). The use of the
Table 1 Physiological variables shown as mean ± SEM of 7, 5 and 5 rats for a-chloralose, thiopental and isoflurane anaesthesia, respectively.
Only lactate concentration was significantly increased under isoflurane anaesthesia compared with both a-chloralose and thiopental (p < 0.01)
using the one-way ANOVA followed by the Newman–Keuls multiple comparison test
a-Chloralose Thiopental Isoflurane
Temperature (C) 37.2 ± 0.2 37.4 ± 0.2 37.7 ± 0.2
Heart rate (min)1) 388 ± 58 335 ± 23 382 ± 29
Mean arterial pressure (mm Hg) 142 ± 13 120 ± 18 132 ± 19
Plasma lactate (mM) 2.8 ± 0.2 3.9 ± 0.5 7.0 ± 1.1
Arterial Ph 7.37 ± 0.02 7.38 ± 0.03 7.37 ± 0.02
PaCO2 (mmHg) 39.3 ± 0.8 40.6 ± 2.8 41.4 ± 1.1
PaO2 (mmHg) 188.2 ± 6.5 179.5 ± 12.9 180.4 ± 14.9
Arterial O2 saturation (%) 99.6 ± 0.1 99.5 ± 0.1 99.5 ± 0.1
Out In
k–1k1
k–3k3
Cout
Cin
CinG
CoutG
Gout
Gin
k–2k2 k–4k4
Fig. 1 The alternating-conformation model. The glucose carrier exists
in four conformations: when loaded, it can isomerise between con-
formations that favour glucose release to either the outer (CoutG) or
the inner (CinG) side of the membrane; in the free form, it exists in two
inter-converting isomers Cout or Cin that are ready to bind glucose in
either of the membrane sides. The rate constants k1 and k-3 define
glucose binding while k-1 and k3 define its dissociation from the carrier.
The rate constants k2 and k-2 or k4 and k-4 reflect the isomerisation of
the loaded or unloaded carrier, respectively. A fast isomerisation of the
unloaded carrier, that is, for k4 and k-4 much larger than the other rate
constants, is equivalent to a simple reversible MM kinetics (Duarte
et al. 2009b). Figure was adapted from Duarte et al. (2009b), where
the relation between rate constants and the kinetic parameters was
explained in detail.
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four-state conformational model of solute carriers to describe
glucose transport across the BBB was previously detailed elsewhere
(Duarte et al. 2009b). Despite the asymmetry of individual glucose
carriers (reviewed in Simpson et al. 2007), the global glucose
transport mechanism across the BBB has been found to approach
symmetry (e.g. Barros et al. 2007; Duarte et al. 2009b), which was
thus assumed in the present model (see discussion). Using this four-
state conformational kinetics, Gbrain as function of Gplasma and time
(t) is then given by
dGbrainðtÞ
dt
¼
Tmax GplasmaðtÞ  GbrainðtÞVd
 
Kt þ GbrainðtÞVd þ GplasmaðtÞ 1þ
GbrainðtÞ
VdKii
  CMRglc ð2Þ
where Gbrain and Gplasma are the concentrations of glucose in brain
(in lmol/g) and in plasma (in mM), Tmax denotes the apparent
maximal transport rate across the BBB (lmol/g/min), Kt and Kii
denote the apparent Michaelis and iso-inhibition constants (in mM),
Vd is the volume of the physical distribution space of glucose in the
brain (0.77 mL/g) (Lund-Andersen 1979).
From eqn 2 it is apparent that if Kii largely exceeds Gbrain, the
model approximates the kinetics of a reversible MM model, which is
equivalent to the four-state conformational model with fast
exchange rates between unloaded carrier conformations (Duarte
et al. 2009b).
Determination of kinetic parameters
The contribution of Gplasma to the measured Gbrain was subtracted
assuming a blood volume in the brain of 35 lL/g (Shockley and
LaManna 1988). The kinetic parameters were estimated for both
four-state conformational model and reversible model of glucose
transport (assuming Kii>>Gbrain, i.e. Gbrain/Kii=0). CMRglc was
considered to be constant in the range of glucose concentrations
analysed. However, as brain glucose levels varied through the
experimental protocol, for the sake of comparison, glucose
consumption was also analysed with an irreversible MM kinetics
for glucose phosphorylation by hexokinase (ATP:D-hexose 6-
phosphotransferase, EC 2.7.1.1). In this case, hexokinase was
considered to have irreversible MM kinetics and fits to the data were
performed with free Vmax
HK but KM
HK constrained to 50 lM (Weil-
Malherbe and Bone 1951; Grossbard and Schimke 1966; Schimke
and Grossbard 1968; Buschiazzo et al. 1970; Gjedde 1982;
Sprengers et al. 1983). If not constrained, KM
HK was poorly
estimated with any of the tested models.
Each model was fitted to Gbrain as function of Gplasma over the
entire measured time courses using the Levenberg–Marquardt
algorithm for non-linear regression, coupled to a Runge–Kutta
method for non-stiff systems to obtain numerical solutions of the
ordinary differential equations. Fit quality was assessed by Monte-
Carlo analysis, in which gaussian noise with the same variance of
fit residuals was added to the best fit and initial conditions were
randomly generated within confidence interval of the obtained
value. Typically, 1000 simulated datasets were created for each
individual analysis. These Monte-Carlo simulations allowed
estimating the standard deviation for each parameter in a single
experiment. Significance of the fitted kinetic parameters was
inferred from t-statistics. The F-statistics was used to compare the
different models that have been fit to each data set. All numerical
procedures were performed in Matlab (The MathWorks, Natick,
MA, USA). Data are shown as mean ± SEM of n experiments
unless otherwise indicated. Effect of anaesthesia on kinetic
parameters was determined by ANOVA followed by Newman–
Keuls multiple comparison tests and considered significant when
p < 0.05.
Results
Reliable quantification of glucose was achieved with a time
resolution of 3 min from 1H NMR spectra acquired in vivo
from a volume of 120 lL located in cortical and hippo-
campal areas (Fig. 2). However, to ensure enough signal to
noise ratio for glucose quantification at euglycaemia, time
resolution of 5 min was preferred as it resulted in CRLB of
glucose consistently bellow 15%. In particular, from all
analysed data-sets, CRLB for glucose were 11–13% at
euglycaemia and decreased to 3% upon glucose infusion.
Gbrain increased at a rate reflecting both glucose transport
across the BBB and continuous glucose consumption
3x
6 5 4 3 2 1 0
Chemical shift (ppm)
Glc Ins
PCr+Cr
G
lu+G
ln
Ins Ins
Tau
P
C
ho+G
P
C
P
C
r+C
r
A
sp
G
A
B
A
NAA
NAA
G
ln
G
lu
G
A
B
A
G
lu+G
ln
G
A
B
A
Ala Lac
Residual 
water
0 min
25 min
50 min
75 min
Glc
Fig. 2 Typical 1H NMR spectra at 9.4 T acquired in vivo during the
time course of glucose infusion. These example spectra were acquired
during 3 min after 0, 25, 50 and 75 min of ‘step-function’ glucose
infusion. Several metabolites are identified in the spectrum, including
discernible resonances of glucose (red label). The expansion on the
right of each spectrum is the respective peak of glucose at 5.22 ppm.
Metabolites in the spectra are assigned as follows: glucose (Glc),
creatine (Cr), phosphocreatine (PCr), myo-inositol (Ins), taurine (Tau),
N-acetylaspartate (NAA), aspartate (Asp), glutamate (Glu), glutamine
(Gln), c-aminobutyrate (GABA), alanine (Ala), lactate (Lac), glycer-
ophosphorylcholine (GPC) phosphorylcholine (PCho), N-acetylaspar-
tylglutamate (NAAG).
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(Fig. 3a and b). Similarly, when glucose in the plasma
dropped to normoglycaemia, that is, upon cessation of
glucose infusion, Gbrain decayed accordingly. The dynamics
of Gbrain measured by
1H NMR spectroscopy in vivo was
thus used to determine rates of consumption and transport,
as well as affinity and inhibition constants. The concentra-
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Fig. 3 Panels (a) and (b) show the best fit of the conformational
(green/blue) and reversible (red/orange) models to Gbrain with BBB as
a single membrane in a representative data set (one rat), under
a-chloralose anaesthesia. Panel (a) shows the fit when constant glu-
cose consumption is assumed. In panel (b), hexokinase was modelled
with a standard MM kinetics. Gplasma was interpolated for the time
scale of Gbrain (gray line). In general, F-statistics indicated good fit
(large f-values) and all determined parameters were significant, as
evaluated with a t-statistics. In this particular case, t(Tmax)=36.2,
t(Kt)=9.40, t(CMRglc)=35.4 with R
2 = 0.966 and f = 557 for the
reversible MM model; t(Tmax)=36.7, t(Kt)=12.2, t(Kii)=12.8,
t(CMRglc)=40.0 with R
2 = 0.969 and f = 450 for the conformational
model. When assuming that hexokinase behaves as a MM enzyme
(with KM
HK=50lM) instead of considering constant CMRglc, for this
particular experiment, t(Tmax)=47.9, t(Kt)=8.76, t(Vmax
HK)=45.9 with
R2 = 0.966 and f = 555 for the reversible MM model; t(Tmax)=29.2,
t(Kt)=8.04, t(Kii)=6.70, t(Vmax
HK)=45.2 with R2 = 0.969 and f = 453 for
the conformational model. Therefore, one can infer that, although fit
adequacy is good with any of the models, metabolic rates are more
significant than apparent affinity and iso-inhibition constants. Panel (c)
shows probability density functions determined from Monte-Carlo
simulations. The graphs include the density function for the confor-
mational and reversible model assuming a single membrane at the
BBB. While rate constants approximated a Gaussian distribution, the
distribution for affinity and iso-inhibition constants was rather de-
scribed with gamma functions that approximated an exponential for
the reversible model. Panel (d) depicts a steady-state analysis of the
present data from rats under a-chloralose (n = 7), isoflurane (n = 5)
and deep thiopental (n = 5) anaesthesia. As all the experiments here
performed had generally three stead-state periods, consisting of
baseline, hyperglycaemia and baseline after glycaemia decay, steady-
state Gbrain measurements in function of Gplasma were used for steady-
state analysis as previously described (Duarte et al. 2009b). Best fit of
the reversible and four-state conformational models is depicted by the
red and green lines, respectively. Results from steady-state analysis
are shown in Table 3.
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tions of other measured metabolites were not significantly
altered upon glucose infusion.
The data resolution obtained from a single experiment led
to significant fits for all of the models of glucose transport, as
determined by f-statistics (Fig. 3a and b). Kinetic parameters
are shown in Table 2 for the rat brain under a-chloralose
anaesthesia. Both Tmax and CMRglc (or Vmax
HK) were
consistently estimated with small calculated errors for both
the reversible and four-state conformational models (Ta-
ble 2), as depicted from high t values and a Gaussian
probability density function (see example in Fig. 3). That
was not the case for the apparent affinity and iso-inhibition
constants that, in most cases, displayed a nearly exponential
probability density function, suggesting that the glucose
transport models were less efficient in constraining Kt and
Kii. In fact, t-statistics indicated that Kt was not significantly
different from zero when using the reversible MM model
(Fig. 3c). The concentration of glucose at half-maximal
transport Kt was however better estimated with the four-state
conformational than with the reversible model (Fig. 3).
Under a-chloralose anaesthesia, Kt was 1.43 ± 0.33 mM.
The iso-inibition constant Kii was 50.3 ± 16.0 mM, which
was not significantly different from when hexokinase activity
was modelled as an irreversible MM enzyme. As it was much
larger than brain glucose concentrations observed in this
study, Kii was less well estimated than the other parameters,
and was associated with larger relative standard deviation.
In addition to the transient changes in brain glucose
content, steady-state Gbrain was available at hyper- and
euglycaemia. Therefore, a steady-state analysis of glucose
transport was performed as previously described (Duarte
et al. 2009b). Fitted Gbrain as function of Gplasma (Fig. 3d)
resulted in Tmax/CMRglc similar to those determined with the
current dynamic strategy (Table 3).
With the estimated kinetic parameters (Table 2), we
simulated Gbrain as function of Gplasma at either non-steady-
state or steady-state (Fig. 4). From these simulations, we
determined normal Gbrain at euglycaemia (i.e. Gplasma of
5.5 mM), to be 0.9 lmol/g with any of the models employed,
consistent with numerous NMR or microdialysis measure-
ments in vivo (reviewed in Barros et al. 2007). To this Gbrain
concentration adds the contribution of Gplasma in a blood
volume of 35 lL/g of brain tissue, and thus the Gbrain
measured by 1H NMR spectroscopy is 1.1 lmol/g, in
agreement with 1.2 ± 0.2 lmol/g measured under a-chloral-
ose at 5.5 ± 0.2 mM of Gplasma (n = 7). From the performed
simulations, we also verified that CMRglc was unaltered at
euglycaemia and above (Fig. 4c).
Table 2 Kinetic parameters of glucose
transport and consumption in the rat brain
as determined in vivo by dynamic 1H NMR
spectroscopy under light a-chloralose
anaesthesia. Tmax, CMRglc and Vmax
HK are
given in lmol/g/min while Kt and Kii and
KM
HK are in mM. Data are mean ± SEM of
seven experiments
Constant CMRglc
With MM kinetics for
hexokinase*
Four-state
conformational model
Tmax 1.03 ± 0.18 Tmax 1.02 ± 0.16
Kt 1.43 ± 0.33 Kt 1.80 ± 0.54
Kii 50.3 ± 16.0 Kii 58.6 ± 20.9
CMRglc 0.52 ± 0.09 Vmax
HK 0.53 ± 0.09
Tmax/CMRglc 2.03 ± 0.21 Tmax/CMRglc** 2.09 ± 0.18
Reversible model Tmax 0.99 ± 0.18 Tmax 0.96 ± 0.18
Kt 0.64 ± 0.27 Kt 1.09 ± 0.48
CMRglc 0.59 ± 0.11 Vmax
HK 0.57 ± 0.11
Tmax/CMRglc 1.68 ± 0.08 Tmax/CMRglc** 1.77 ± 0.08
*KM
HK was fixed at 50 lM; **Tmax/CMRglc calculated for Gbrain = 1 lmol/g.
Table 3 Kinetic parameters of glucose transport and consumption in the brain as determined in vivo by 1H NMR spectroscopy at steady-state
under a-chloralose (n = 7), isoflurane (n = 5) and thiopental (n = 5) anaesthesia. BBB was considered to behave as a single membrane. Tmax/
CMRglc is dimensionless and both Kt and Kii are in mM. Results of the best fit are shown with confidence intervals
a-Chloralose Isoflurane Thiopental
Four-state conformational model Tmax/CMRglc 2.06 (0; 4.57) 2.75 (0; 7.62) 1.84 (0.70; 2.98)
Kt 1.49 (0; 10.45) 1.54 (0; 17.67) 0
Kii 26.4 (0; 227.1) 13.4 (0; 82.6) 347.0 (0; 6041.0)
(R2 = 0.859) (R2 = 0.860) (R2 = 0.899)
Reversible model Tmax/CMRglc 1.73 (1.56; 1.91) 1.96 (1.71; 2.20) 1.82 (1.70; 1.94)
Kt 0.32 (0; 1.70) 0 0.10 (0; 1.10)
(R2 = 0.907) (R2 = 0.887) (R2 = 0.899)
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As cerebral glucose metabolism is dependent on neuronal
activity, we tested the effect of deep thiopental anaesthesia in
the estimated kinetic metabolic parameters. Sodium thiopen-
tal was administered at a dose able to induce iso-electricity in
the rat brain. In comparison to a-chloralose anaesthetized
rats, Tmax and CMRglc were reduced by 42 ± 10% (n = 5,
p < 0.05) and 49 ± 4% (n = 5, p < 0.05), respectively, while
Kt and Kii were not significantly different under both
anaesthesia conditions (Fig. 5a). Tmax and Kii tended to be
respectively higher and lower under isoflurane anaesthesia
than under a-chloralose, although not significantly different.
This was confirmed by higher glucose levels under isoflurane
anaesthesia compared with a-chloralose at steady-state
(Fig. 3d). Figure 5b show simulations of Gbrain dynamics
for a given Gplasma using the kinetic parameters obtained for
each anaesthesia protocol. In particular, deep thiopental
anaesthesia caused a larger depression in CMRglc upon than
in Tmax and thus led to glucose accumulation in the brain.
Discussion
Cerebral glucose transport and metabolism
The metabolic rate of the brain is closely related to the
glycolytic rate as glucose provides most cerebral energy
supply (Siesjo 1978). There is abundant evidence that
GLUT1 is the main glucose carrier at the BBB and that,
under normal physiology, it is not limiting for the overall
brain glucose consumption rate (reviewed in Barros et al.
2007; Simpson et al. 2007). Glucose concentration in the
brain is thus dependent on facilitated diffusion at the BBB
and glucose phosphorylation by hexokinase. This study was
designed to test the hypothesis that simultaneous measure-
ment of glucose concentrations in plasma and brain upon
modification of plasma glucose levels allow reliable estima-
tion of kinetic parameters of cerebral glucose homeostasis,
including the glucose metabolic rate.The present data shows
that, by simultaneously measuring plasma and brain glucose
concentrations, Tmax and CMRglc can be independently
determined in vivo and in a non-invasive way. In addition,
using the four-state conformational model of glucose trans-
port, we simultaneously determined Tmax, Kt, Kii and
CMRglc. Under a-chloralose anaesthesia, CMRglc of
0.52 ± 0.09 lmol/g/min was similar to determinations using
[1,6-13C]glucose as tracer and detection by 13C NMR
spectroscopy in the whole brain (Duarte et al. 2011a) and
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Fig. 4 The estimated kinetic parameters (Table 2) were used to
simulate Gbrain for a given Gplasma function at non-steady-state (a) and
steady-state (b). Black line represents plasma glucose function. Sim-
ulations were performed with the conformational and reversible mod-
els assuming either constant CMRglc (solid lines) or MM kinetics for
hexokinase with KM
HK fixed at 50 lM (dashed lines). In (b), the graph
on the right is an expansion for plasma glucose bellow 6 mM. Panel (c)
shows the resulting CMRglc as function of Gbrain, validating the
assumption of invariable CMRglc above 1 lmol/g of Gbrain.
(a)
(b)
Fig. 5 Panel (a) shows the effect of isoflurane and deep thiopental
anaesthesia on kinetic parameters of cerebral glucose transport and
consumption, in comparison to light a-chloralose anaesthesia. Glu-
cose kinetics was evaluated with the four-state conformational model.
Tmax and CMRglc are given in lmol/g/min while Kt and Kii are in mM.
Data are mean ± SEM of 7, 5 and 5 rats for a-chloralose, thiopental
and isoflurane anaesthesia, respectively. Data comparison was per-
formed with one-way ANOVA followed by the Newman–Keuls multiple
comparison test (*p < 0.05, **p < 0.01). Panel (b) depicts mathemat-
ical simulation of Gbrain levels as function of a given Gplasma (black line)
using the kinetic parameters determined for each of the anaesthesia
types with the four-state conformational model.
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to measures by autoradiography in the cortex and hippo-
campus (Ueki et al. 1992; Nakao et al. 2001), which are
areas encompassed in the current VOI. Note that a small
portion of the spectroscopy volume is constituted by white
mater of the corpus callosum that has smaller CMRglc than
gray matter (e.g. Sokoloff et al. 1977; Archer et al. 1990). In
fact, through the different regions of the brain, CMRglc
values ranging from 0.54 to 1.97 lmol/g/min and from 0.33
to 0.40 lmol/g/min were respectively reported for the gray
matter and for white matter of the conscious rat (Sokoloff
et al. 1977). The ratio of Tmax to CMRglc determined in the
present study is in agreement with previous findings in the rat
brain under a-chloralose anaesthesia (Duarte et al. 2009a,b,
2011a; Lei et al. 2010). The apparent affinity constant Kt was
in the range of previous reports for steady-state experiments
(Duarte et al. 2009b). Kii was found to be much larger than
Gbrain and in the same order of magnitude of that determined
by steady-state models of glucose transport (Barros et al.
2007; Duarte et al. 2009b).
Like traditional steady-state models (e.g.Gruetter et al.
1998; Duarte et al. 2009a), the present dynamic model was
designed with the assumption of symmetric glucose
transport at the BBB. Transport asymmetry reflects differ-
ent KM and Vmax for glucose uptake and release. However,
the occurrence of nearly equal density of glucose asym-
metric carriers on both sides of the BBB, that is, in luminal
and abluminal membranes of the endothelium, presumably
results in cancelation of the intrinsic asymmetry of
individual carrier proteins (discussed in Barros et al.
2007; Simpson et al. 2007). Therefore, in previous studies,
glucose diffusion at the BBB in vivo was found compatible
with symmetric transport (Barros et al. 2007; Duarte et al.
2009b). Furthermore, a concentration gradient drives glu-
cose transport from the plasma into the brain parenchyma
and does not favour glucose release from the brain.
The determined kinetic parameters are thus apparent
constants that describe the global mechanism of net
glucose transport.
Glucose accumulated in the brain upon glucose infusion, as
consequence of the equilibrative nature of glucose transport
across the BBB and a glycolytic flux operating close to its
maximum rate, with CMRglc unaltered at euglycaemia and
above (Fig. 4c). In line with this, when glucose infusion
ceased, the decay in cerebral glucose concentration was
delayed and strongly dependent on glucose consumption that
starts with its phosphorylation by hexokinase. We further
determined kinetic parameters of the hexokinase activity,
assuming irreversible MM kinetics. Without fixing any
constraint to the fitting, for example with the conformational
model of glucose transport, the apparent KM of hexokinase
was found to be 0.11 ± 0.04 mM for brain glucose (data not
shown). However, as this parameter was poorly estimated and
not significantly different from zero with any of the models,
fits to the data were performed with KM
HK constrained to
50 lM, in accordance to the KM of cytosolic hexokinase
isolated from the rat brain ranging from 40 to 67 lM
(Grossbard and Schimke 1966; Schimke and Grossbard 1968;
Sprengers et al. 1983). KM
HK was also determined to be
50 lM in rat brain extracts (Weil-Malherbe and Bone 1951),
and to range between 30 to 40 lMwhen indirectly calculated
from experiments with radio-labelled glucose analogs (Bus-
chiazzo et al. 1970; Gjedde 1982). With KM
HK set to 50 lM
for glucose, under a-chloralose anaesthesia, apparent Vmax
HK
was 0.53 ± 0.09 lmol/g/min when determined with the four-
state conformational model. This observation confirms that, in
the conditions of the present study, brain hexokinase operates
close to its maximum rate: CMRglc was 0.52 ± 0.09 lmol/g/
min. In line with this, we estimated from the present results
that normal glucose concentrations in the brain are close to
1 lmol/g (much larger than KM
HK) at euglycaemia, in
accordance to previous NMR or microdialysis measurements
(reviewed in Barros et al. 2007). This concentration of
glucose, which is mainly dependent on transport and
consumption rates, is similar in both brain interstice and
cytosol of brain cells, as suggested by comparison of
diffusion properties of brain glucose and exclusively intra-
cellular brain metabolites (Pfeuffer et al. 2000). However, 1H
NMR spectroscopy does not allow distinguishing the com-
partments where glucose is utilised. Nevertheless, the results
by Pfeuffer et al. (2000) are in accordance with a fast and
non-limiting transport across neuronal and glial cell mem-
branes, where GLUT1 concentration largely exceeds that of
the luminal and abluminal membranes of the endothelium
(discussed in Simpson et al. 2007).
Effects of anaesthesia on glucose homeostasis
The cerebral metabolic rate of glucose consumption is
regionally and activity-dependent (e.g.Sokoloff et al. 1977;
Ueki et al. 1992; Linde et al. 1999). CMRglc increases upon
somatosensorial stimulation under a-chloralose anaesthesia
(Ueki et al. 1992) and is reduced upon isoelectricity (Choi
et al. 2002). Therefore, we further tested the capability of
determining alterations of glucose uptake and consumption
upon modulation of brain activity by anaesthesia conditions.
In addition to a-chloralose anaesthesia, thiopental and
isoflurane were tested.
In the present metabolic models of brain glucose homeo-
stasis, kinetic constants are apparent values because modu-
lation effects, such as activity regulation of carriers (e.g.
known for ATP, reviewed in Carruthers 1986) and carrier
translocation to the membrane, were not taken in account.
Therefore, inhibitory or stimulatory effects on glucose
diffusion through the BBB will be reflected by alterations
in Tmax, Kt or Kii, while modifications in glucose consump-
tion will be depicted by modified value of CMRglc or Vmax
HK
(with KM
HK set constant).
Barbiturates are effective depressors of the CNS with
actions primarily on the GABAA receptor, but may also
 2012 The Authors
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interact with glutamate receptors and voltage-gated ion
channels. Along with reduction in synaptic activity, barbi-
turates are also known to depress energy metabolism. For
example, they inhibit the oxidation of NADH in the
respiratory chain (Aldridge and Parker 1960; Chance et al.
1963), inhibit glucose phosphorylation (Bielicki and Kriegl-
stein 1976) and thus reduce CMRglc (Strang and Bachelard
1973; Sokoloff et al. 1977; Choi et al. 2002), and inhibit
the capability of GLUT1 to transport glucose (Honkanen
et al. 1995; Haspel et al. 1999; Stephenson et al. 2000). In
accordance, our results showed a depression of both
glucose transport at the BBB and glucose consumption in
vivo, as indicated by reduced Tmax and CMRglc, compared
with light a-chloralose anaesthesia. Up to our knowledge,
thiopental has not been widely employed in studies of brain
glucose utilization, in contrast to pentobarbital. In a
precedent study of glucose transport at steady-state (Lei
et al. 2010), we determined that, relative to a-chloralose,
deep thiopental anaesthesia induces a 47% increase in Tmax/
CMRglc, which implies a larger reduction in glucose
consumption than in transport, and leads to higher brain
glucose content, as observed in the present study (Fig. 5).
Sokoloff et al. (1977) observed a reduction in CMRglc
under thiopental anaesthesia (at a lower dose than in the
present study) compared with conscious rats, while a 13C
NMR spectroscopy study under deep pentobarbital anaes-
thesia reported CMRglc of 0.33–0.38 lmol/g/min for the
whole rat brain (Choi et al. 2002). At a lower dose of
pentobarbital, CMRglc was found to range from 0.42 to
0.57 lmol/g/min (Cunningham et al. 1986). Comparing
directly different types of anaesthesia conditions, for
example Linde et al. (1999) found CMRglc to be 0.66 and
0.33 lmol/g/min in the conscious rat and under pentobar-
bital anaesthesia, respectively. In summary, the inhibition of
glucose phosphorylation and concomitant reduction of
CMRglc under deep thiopental anaesthesia, in comparison
to light a-chloralose anaesthesia, unequivocally demon-
strated the capability of detecting modulation of glucose
metabolism with the present non-invasive strategy.
Brain glucose homeostasis is affected by halogenated
ethers that are frequently used as anaesthetics, namely
isoflurane (Noda et al. 2003) and enflurane (Myers and
Shapiro 1979). Therefore, we finally assayed glucose
transport and consumption kinetics under isoflurane anaes-
thesia and found similar kinetic parameters compared with
a-chloralose anaesthesia. However, Tmax had a tendency to
higher values and Kii was generally lowered then when
using a-chloralose anaesthesia, resulting in higher brain
glucose levels at steady-state (see Fig. 3d), which is a
recurrent observation in many 1H NMR spectroscopy
studies in vivo under isoflurane at euglycaemia (e.g.
Mlyna´rik et al. 2006, 2008; Kulak et al. 2010; Duarte
et al. 2011b).
Conclusion
From the present results, we conclude that a four-state
conformational model allows reliable determination of kinet-
ics of both glucose uptake and consumption upon dynamic
simultaneous measurement of plasma and brain glucose
concentration changes. This method can therefore be an
alternative to other non-invasive standard methods to deter-
mine glucose uptake and consumption that mostly relied on
the utilization of isotope-enriched glucose or glucose analogs.
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